Leukemia regression by vascular disruption and antiangiogenic therapyGerard J. Madlambayan, Christopher R. Cogle, Marda Jorgensen et al.|Blood|2010Cited by 77
AML Regression by Vascular Disruption with OXi4503 and Anti-Angiogenesis with Bevacizumab.Gerard J. Madlambayan, Christopher R. Cogle, Amy Meacham et al.|Blood|2009Cited by 0